Huacuja ÁF, Gómez DM, Ortiz VJC, Soberanes VB, Arévalo MV, Morales VE, Sánchez-Reyes L, Fanghänel G

Language: Spanish
References: 124
Page: 73-88
PDF size: 443.30 Kb.

ABSTRACT

With the objective of presenting the advances in the knowledge of the effects of the statins not related directly with the decrease of the cholesterol levels, it was made a revision of the main on line scientific medical data of the last 10 years, as Medscape, PubMed, Google, Educomsa, Ovid, Edumed, Science Direct and Elsevier. Nowadays the statins had modified the therapy of the dyslipidemias, due to the powerful hypolipemiant effect. Decreased incidence of the cardiovascular events occurs during the first year of statin therapy. The existence of pleiotropics effects beyond its cholesterol lowering actions has been proposed. Due to its lipophilic capacity, the majority of the statins traspass the cellular membrane and inhibit the proliferation of the smooth muscular cell and the migration induced by growing factors, what influence in the process related with the stability of the plaque and the atherothrombosis. Statin improve the endothelial stability, due to the increase production and availability of the nitric oxide (NO) in the endothelial cell. Several of these effects are possibly due to its capacity to limit the synthesis of important isoprenoids intermediaries (fernesil or geranilgeranil), that are used as lipidic ankles for several molecules of intercellular signalization like the GTPasas path and the Rho proteins, increasing the production and availability of the NO. The statins modify the expression endothelial KLF2 gene which inhibits NFkB, crucial mediator of the proinflammatory response. These advances in the knowledge of the actions of the statins, had allowed the use only of statin in VIH/AIDS, Alzheimer’s disease, dementia senile, collagen disorders and osteoporosis.

REFERENCES

1. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML- 236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 1876; 29: 1346-1348.

2. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl- coenzyme A reductase and a cholesterol-lowering agent. Proc Nat Acad Sci 1980; 77: 3957-3961.

3. Cilla Jr DD, Whitfield LR, Gibson DM et al. Multiple-dose pharmacokinetics, pharmacodynamics and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996; 60: 687-95.

4. Brown AS, Bakker-Arkema RG, Yellen L et al. Treating patients with documented atherosclerosis of National Cholesterol Education Program recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin, and simvastatin. J Am Coll Cardiol 1998; 32: 665-672.

5. Horsmans Y. Different metabolism of statins: importance in drug-drug interactions. Eur Heart J 1999; 1 (Suppl 1): 7-12.

6. Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27: 94-103.

7. Brown MS, Goldstein JL. Multivalent feedback of HMG CoA reductasa, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lip Res 1980; 21: 505-517.

8. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.

9. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease the atorvastatin versus revascularization treatment investigators. N Engl J Med 1999; 341: 70-76.

10. Corsini A, Bellosta S, Baetta R. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.

11. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG CoA reductase. Science 2001; 292: 1160-1164.

12. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.

13. Jones P, Kofonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998; 81: 582-587.

14. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390-400.

15. Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 138-39.

16. Scandinavian Simvastatin Survival Study Group. Baseline scrum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-75.

17. Jukema JW, Bruschke AV, van Bovcn AJ, Reiber JH, Bat ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.

18. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-45.

19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators (CARE). N Engl J Med 1996; 335: 1001-9.

20. The Long-term Intervention with Pravastatin in Ischemia Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.

21. Aviram M, Fuhrmasn B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cell: role prooxidants vs oxidants. Mol Cell Biochem 1998; 188: 149-59.

22. Furberg C, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87.

23. Amoroso G, Van Boven AJ, Crijns HJ. Drug Therapy or coronary angioplasty for the treatment of coronary artery disease. Am Heart J 2001; 141: S22-5.

24. Pitt B, Waters D, Brown WV, van Boven AJ, Schwarts L, Title LM et al. Aggressive lipid-lowering therapy compared with angioplasty instable coronary artery disease. Atorvastatin versus revascularization treatment investigator (AVERT). N Engl J Med 1999; 341: 70-6.

25. Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults. Adult Treatment Panel III. JAMA 2001; 285: 2486-97.

26. La Rosa JC, Grundy SM, Waters DD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Treating to New Targets (TNT). N Engl J Med 2005; 352: 1425-35.

27. Grundy SM, Cleeman JI, Bairey MC, Brewer HB, Clark LT, Hunninghake DB et al. For the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004; 110: 227-39.

28. Corsini A, Raitieri M, Sama MR, Fumangali R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharm Res 1991; 23: 173-180.

29. Treasure CB, Klein JL, Weintraub, Talley JD, Stillabower ME, Kosinski AS et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-487.

30. Anderson TJ, Mereclüh IT, Yeung AC, Frei B, Sclwyn AP, Ganz I. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.

31. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.

32. Strocs ESG, Koomans IIA, de Bruin TWA, Rabclink TJ. Vascular function in the forearm of hypercholesterolaemic patients of and on lipid-lowering medication. Lancet 1995; 346: 467-471.

33. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-328.

34. Eichstadt HW, Eskotter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by shortterm fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122-125.

35. Moncada S, Higgs EA. L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.

36. López-Farre A, Caramelo C, Esteban ML, Alberola L, Millás I, Monton M et al. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 1995; 91: 2080-88.

37. Radomski MW, Palmer RMJ, Montada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-58.

38. López-Farré A, Riesco A, Digiuni E, Mosquer JR, Caramelo C, Sánchez de Miguel L, Millás I, de Frutos T, Cernadas MR, Montón M, Alonso J, Casado S. Aspirin stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation 1996; 94: 83-87.

39. López-Farré A, Riesco A, Espinosa G, Digiuni E, Cernadas MR, Álvarez V et al. Effects of endothelin-1 an neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993; 88: 1166-71.

40. Yoshizumi M, Perella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.

41. Wassmann S, Nickening C. Interrelationship of free oxygen radicals and endothelial dysfunction by statin. Endothelium 2003; 10: 23-33.

42. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 1990.

43. Hoffman GR, Nassar N, Cerione RA. Structure of the Rho family GTP-binding protein Cds42 in complex with the multifunctional regulators Rho GDI. Cell 2000; 100: 345-56.

44. Nobes CD, Hall A. Rho, Rac and Cdc42 GTPases regulate the assembly of multimolecular with actin stress fiber, lamellipodia and filopodia. Cell 1995; 81: 53-62.

45. Brills S, Li S, Lyman CW, Chuch DM, Wasmuth JJ, Bemards A et al. The Ras GTPase-activating protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with clamodulin and Rho family GTPases. Mol Cell Biol 1996; 16: 4869-78.

46. Takai Y, Susaki T, Motozaki T. Small GTP-binding protein. Physiol Rev 2001; 81: 153-208.

47. Zhong H, Voll R, Gosh S. Phosphorylation of NF-kB by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1: 661-671.

48. Lallemand D, Spyrou G, Yaniv M, Pfarr CM. Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 1997; 14: 819-30.

49. Chen C, Zhou Y, Zhou Z, Sun X, Otto KB, Uht RM, Dong JT. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 2004; 330: 133-42.

50. Wächtershäuser A, Akoglu B, Stein J. HMG.CoA reductase inhibitor mevastatin enhances the growth inhibitory effecty of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 2001; 22: 1061-67.

51. Yokoyama K, Ishibashi T, Ohkawara H, Kimura J, Matsuoka I, Sakamoto T et al. HMG-CoA Reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 2002; 105: 962.

52. Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005; 45: 89-118.

53. Maack C, Kartes T, Kilter H et al. Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and Represents a Target for Statin Treatment, German; Institute of Molecular Cardiobiology. Circulation 2003; 108: 1567-1574.

54. Jalil J, Lavandero S, Chiang M, Ocaranza MP. La vía de señalización Rho/Rho-cinasa en la enfermedad y el remodelado cardiovascular. Rev Esp Cerdiol 2005; 58: 951-61.

55. Shimokawa H, Takeshita A. Rho-Kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-75.

56. Vojtek AB, Der CJ. Increasing complexitin of the Ras signaling pathway. J Biol Chem 1998; 273: 19925-8.

57. Khorravi-Far R, Campbell S, Rossman KL, Der CJ. Increasing complexity of Ras Signal Transduction: Involvement of Rho Family Proteins. Adv Cancer Res 1998; 72: 55-105.

58. Dodemont HJ, Soriano P, Quax WJ, Ramaekers F, Leutra JA, Groenen MAM et al. The genes coding for the cytoskeletal proteins actin and vimentin in warm-blooded vertebrates. EMBO J 1982; 1(2): 167-71.

59. Barandier C, Ming X, Yang Z. Small G Proteins as Novel Therapeutic Targets in Cardiovascular Medicine. N Physiol Sciences 2003; 18: 18-22.

60. MacKay DJ, Hall A. Rho GTPases. J Biol Chem 1998; 273: 20685-88.

61. Palmby TR, Abe K, Der ChJ. Critical Role of the Pleckstrin Homology and Cysteine-rich Domains in Vav Signaling and Transforming Activity. J Biol Chem 2002; 277: 39350-9.

62. Kyung Hee Hong, Jewon Ryu, Ki Hoon Han. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-7.

63. Ishibashi T, Nagata K, Ohkawara H, Sakamoto T, Yokoyama K, Shindo J, Sugimoto K, Sakurada S, Takuwa Y, Teramoto T, Maruyama Y. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta 2002; 1590: 123-30.

64. Kaartinen V, Haataja L, Nagy A, Heisterkamp N, Groffen J. TGFβ3-induced activation of RhoA/Rho-kinase pathway is necessary but not sufficient for epithelio-mesenchymal transdifferentiation: Implications for palatogenesis. Int J Mol Med 2002; 9: 563-570.

65. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004; 109: 3149-53.

66. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib Fruchart J et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-1432.

67. Dechend R, Müller D, Koon Park J, Fiebeler A, Haller H, Luft FC. Statins and angiotensin II-induced vascular injury. Nephrol Dial Transplant 2002; 17: 349-353.

68. Mraiche F, Cena J, Das D, Vollrath B. Effects of statins on vascular function of endothelin-1. Br J Pharmacol 2005; 144: 715-26.

69. Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 2000; 32: 1103-21.

70. Bicker JJ. Kruppel-like factor: three fingers in many foots. J Biol Chem 2001; 276: 34355-58.

71. Suzuki T, Aizawa K, Matsumura T, Nagai R. Vascular implications of Krüppel-like family of transcription factors. Arterioscler Thromb Vasc Biol 2005; 25: 1135-41.

72. Barnes PJ, Karin M. Nuclear Factor-kB. A pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997; 336: 1066-71.

73. Velásquez TA, Gariglio VP. Posible papel del factor de transcripción ap1 en la regulación tejido-específica del papilomavirus humano. Rev Invest Clin 2002; 54: 231-42.

74. Welter JF, Crish JJ, Agarwal C, Eckert RL. Fos related antigen (Fra-1), Jun B and Jun D activate human involucrin promoter transcription by binding to proximal and distal AP-1 sites to mediate phorbol ester effects on promoter activity. J Biol Chem 1995; 270: 12614-22.

75. Brand K, Page S, Wall AK, Neumeier D, Baeuerle PA. Role of nuclear factor- kappa B in atherogenesis. Exp Physiol 1997; 82: 297-304.

76. de Martin R, Hoeth M, Hofer-Warbinek R, Sumid JA. The transcription factor NF-kB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20: e83-e88.

77. Traenckner EB, Pahl HL, Henkel T, Scmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IkBalfa on serines 32 and 36 controls IkBalfa proteolysis and NF-kB activation in response to diverse stimuli. EMBO J 1995; 14: 2876-83.

78. Mercurio F, Zhu H, Murria BW, Shevchenko A, Bennet BL, Li JW et al. IKK-1 and IKK-2: cytokine-activated IkB kinases essential for NF-kB activation. Science 1997; 278: 860-6.

79. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-Associated Kinase Pathway Selectively Regulates Thrombin-Induced Intercellular Adhesion Molecule-1 Expression in Endothelial Cells via Activation of I{kappa}B Kinase {beta} and Phosphorylation of RelA/p65. J Immunol 2004; 173: 6965-72.

80. Li W, Asagami T, Matsushita H, Lee K, Tsao PS. Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J Pharmacol Exp Ther 2005; 313: 557-62.

81. May MJ, Ghosh S. Signal transduction: IkB Kinases: Kinsmen with Different Crafts. Science 1999; 284: 271-3.

82. Jiang B, Xu S, Hou X, Pimentel DR, Brecher P, Cohen RA. Temporal Control of NF-{kappa}B Activation by ERK Differentially Regulates Interleukin-1{beta}-induced Gene Expression. J Biol Chem 2004; 279: 1323-29.

83. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. Long pentraxin PTX3 Up regulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 2002; 22: 782-7.

84. Shi C, Zhang X, Chen Z, Robinson MK, Simon DI. Leukocyte Integrin Mac-1 Recruits Toll/Interleukin-1 Receptor Superfamily Signaling Intermediates to Modulate NF-{kappa}B Activity. Circulation Research 2001; 89: 859-65. 85. Middleton G, Hamanoue M, Enokido Y, Wyatt S, Pennica D, Jaffray E, Hay RT, Davies AM. Cytokine-induced nuclear factor kappa b activation promotes the survival of developing neurons. J Cell Biol 2000; 148: 325-332.

85. Middleton G, Hamanoue M, Enokido Y, Wyatt S, Pennica D, Jaffray E, Hay RT, Davies AM. Cytokine-induced nuclear factor kappa b activation promotes the survival of developing neurons. J Cell Biol 2000; 148: 325-332.

86. Jobin C, Sartor RB. The Ikappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am J Physiol 2000; 278: C451-462.

87. Hayashi T, Faustman D. Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappa B activation and prevention of tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 2000; 275: 5238-47.

88. Castrillo A, Díaz-Guerra MJM, Hortelano S, Martín-Sanz P, Boscá L. Inhibition of Ikappa B Kinase and Ikappa B Phosphorylation by 15-Deoxy-Delta 12,14-Prostaglandin J2 in Activated Murine Macrophages. Mol Cell Biol 2000; 20: 1692-98.

89. Jaclyn L, Karin M. The carboxyl-Terminal region of IkB kinase (IKKa) is required for full IKK activation. Mol Cell Biol 2002; 22: 6573-81.

90. Hehner SP, Hofmann TG, Ushmorov A, Dienz O, Wing-Lan Leung I, Lassam N, Scheidereit C, Dröge W, Schmitz ML. Mixed-Lineage Kinase 3 Delivers CD3/CD28-Derived Signals into the Ikappa B Kinase Complex. Mol Cell Biol 2000; 20: 2556-68.

91. Kawakami T, Chiba T, Suzuki T, Iwai K, Yamanaka K, Minato N et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J 2001; 20: 4003-12.

92. Regula KM, Ens K, Kirshenbaum LA. IKKbeta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J Biol Chem 2002; 277: 38676-82.

93. Antonsson A, Hughes K, Edin S, Grundstrom T. Regulation of c-Rel Nuclear Localization by Binding of Ca2+/Calmodulin. Mol Cell Biol 2003; 23: 1418-1427.

94. Reynaert NL, Ckless K, Korn SH, Vos N, Guala AS, Wouters EFM, van der Vliet A, Janssen-Heininger YMW. From the Cover: Nitric oxide represses inhibitory {kappa}B kinase through S-nitrosylation. Proc Natl Acad Sci USA 2004; 101: 8945-50.

95. O’Mahony AM, Montano M, Van Beneden K, Chen LF, Greene WC. Human T-cell lymphotropic virus type 1 tax induction of biologically active NF {kappa}B requires I{kappa}B kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem 2004; 279: 18137-45.

96. Doerre S, Mesires KP, Daley KM, McCarty T, Knoetig S, Corley RB. Reductions in I{kappa}B{epsilon} and changes in NF-{kappa}B activity during B lymphocyte differentiation. J Immunol 2005; 174: 983-91.

97. Ortego M, Bustos C, Hernandez-Presa, Tuñon J, Diaz C, Hernandez G et al. Atorvavstatin reduces NF-Kappa B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.

98. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA Jr, Garcia-Cardena G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005; [Epub ahead of print].

99. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond) 2004; 106: 215-7.

100. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-88.

101. Nakagami H, Liao JK. Statins and myocardial hypertrophy. Coronary Artery Disease 2004; 15: 247-50.

102. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y et al. Global analysis of RNA expression profile in human vascular cell treated with statins. J Atheroscleros Thromb 2004; 11: 62-72.

103. Laufs UK, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Current Atherosclerosis Reports 2003; 5: 372-378.

104. Chen MS, Xu FP, Wang YZ, Zhang GP, Yi Q, Zhang HQ, Luo JD. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004; 37: 889-96.

105. Masamura K, Oida K, Kanebara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endotelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23: 512-7.

106. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 2005; 98: 661-6.

107. Fichtenbaum CJ, Gerber JG, Rosenkrantz SL. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16(4): 569-577.

108. del Real G, Jiménez-Baranda S, Lacalle RA, Mira E, Lucas P, Gómez-Mouton C et al. Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002; 196: 293-301.

109. Nguyen DH, Taub DD. Targeting lipids to prevent HIV infection. Mol Interv 2004; 4: 318-20.

110. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200: 541-7.

111. Thorp EB, Gallagher TM. Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. J Virol 2004; 78: 2682-92.

112. Choi KS, Aizaki HH, Lai MM. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J Virol 2005; 79: 9862-71.

113. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.

114. Fassbender K, Simons M, Bergmann C, Stroick M. Simvastatin strongly reduces levels of Alzheimer’s disease betaamyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-61.

115. 115.Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of demential. Lancet 2000; 356: 1627-31.

116. Krabbe KS, Pederson M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerentology 2004; 39: 687-99.

117. Kida Y. Statins and rheumatoid arthritis. Lancet 2004; 364: 1854-5.

118. Van Denderen JC, Peters M, Halm VV, Horst-Bruinsma IV, Dijkmans B, Nurmohamed M. Statin therapy might be beneficial for treating patients with ankylosing spondylitis. Ann Rheum Dis 2005; [Epub ahead of print].

119. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol 2005; 32: 2095-2101.

120. Riboldi P, Gerosa M, Meroni PL. Statins and autoimmune diseases. Lupus 2005; 14(9): 765-8.

121. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005; 7: 55-61.

122. Mundy G, Garrett R, Harris S, Gutiérrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 946-9.

123. Reid IR, Hague W, Emberson J. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 2001; 357: 509-12.

124. Wang PS, Solomon DH, Mogun H. HMG-Co A reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-6.